Nifty
Sensex
:
:
12130.15
41295.57
4.25 (0.04%)
-27.43 (-0.07%)

Pharmaceuticals & Drugs

Rating :
69/99  (View)

BSE: 532523 | NSE: BIOCON

312.40
6.30 (2.06%)
20-Feb-2020 | 9:34AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  305.95
  •  312.50
  •  305.80
  •  306.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  581203
  •  1815.68
  •  320.98
  •  211.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 36,726.00
  • 43.80
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 38,091.80
  • 0.16%
  • 5.55

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 1.38%
  • 11.42%
  • FII
  • DII
  • Others
  • 16.09%
  • 4.21%
  • 6.23%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.82
  • 12.28
  • 12.32

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.45
  • 14.90
  • 7.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.92
  • 12.70
  • 14.93

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.03
  • 31.76
  • 44.60

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.86
  • 4.70
  • 5.73

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.19
  • 21.54
  • 26.58

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Net Sales
1,748.10
1,540.80
13.45%
1,572.20
1,321.00
19.02%
1,465.90
1,123.80
30.44%
1,528.80
1,169.50
30.72%
Expenses
1,303.90
1,160.10
12.40%
1,169.40
981.40
19.16%
1,028.40
886.00
16.07%
1,125.80
936.50
20.21%
EBITDA
444.20
380.70
16.68%
402.80
339.60
18.61%
437.50
237.80
83.98%
403.00
233.00
72.96%
EBIDTM
25.41%
24.71%
25.62%
25.71%
29.85%
21.16%
26.36%
19.92%
Other Income
35.80
25.60
39.84%
38.40
54.40
-29.41%
24.10
68.80
-64.97%
28.20
67.50
-58.22%
Interest
17.70
18.60
-4.84%
13.80
18.80
-26.60%
16.60
17.60
-5.68%
15.90
16.90
-5.92%
Depreciation
144.00
116.70
23.39%
131.60
112.20
17.29%
124.20
99.10
25.33%
119.80
95.30
25.71%
PBT
318.30
276.80
14.99%
363.30
451.80
-19.59%
320.80
189.90
68.93%
295.50
188.30
56.93%
Tax
84.80
46.10
83.95%
100.10
73.20
36.75%
85.20
52.10
63.53%
40.90
40.70
0.49%
PAT
233.50
230.70
1.21%
263.20
378.60
-30.48%
235.60
137.80
70.97%
254.60
147.60
72.49%
PATM
13.36%
14.97%
16.74%
28.66%
16.07%
12.26%
16.65%
12.62%
EPS
1.69
1.81
-6.63%
1.80
2.96
-39.19%
1.72
1.00
72.00%
1.78
1.09
63.30%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
6,315.00
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
2,367.82
Net Sales Growth
22.50%
33.73%
5.97%
16.24%
8.34%
7.39%
15.77%
19.11%
15.53%
-23.73%
 
Cost Of Goods Sold
1,967.60
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
1,337.54
Gross Profit
4,347.40
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
1,030.27
GP Margin
68.84%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
59.17%
59.83%
43.51%
Total Expenditure
4,627.50
4,120.70
3,294.30
2,911.60
2,579.60
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
1,896.33
Power & Fuel Cost
-
239.80
189.00
156.40
184.70
176.70
162.40
142.60
97.20
82.00
67.63
% Of Sales
-
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
4.66%
4.54%
2.86%
Employee Cost
-
1,165.30
931.10
747.00
610.10
533.40
466.30
389.40
307.60
238.80
242.76
% Of Sales
-
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
14.74%
13.22%
10.25%
Manufacturing Exp.
-
451.30
335.70
391.50
320.90
81.20
62.90
95.20
113.20
81.60
68.63
% Of Sales
-
8.18%
8.14%
10.06%
9.59%
2.63%
2.19%
3.83%
5.43%
4.52%
2.90%
General & Admin Exp.
-
53.00
56.80
21.70
42.60
165.70
131.80
122.20
93.20
82.40
79.09
% Of Sales
-
0.96%
1.38%
0.56%
1.27%
5.36%
4.58%
4.92%
4.47%
4.56%
3.34%
Selling & Distn. Exp.
-
277.50
98.20
107.40
100.80
108.70
118.90
99.60
89.40
62.40
56.49
% Of Sales
-
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
4.28%
3.46%
2.39%
Miscellaneous Exp.
-
37.20
47.40
41.00
30.10
72.70
61.80
52.90
256.70
940.80
56.49
% Of Sales
-
0.67%
1.15%
1.05%
0.90%
2.35%
2.15%
2.13%
12.30%
52.09%
1.87%
EBITDA
1,687.50
1,393.70
829.10
979.50
767.80
695.80
687.10
539.00
277.20
-407.40
471.49
EBITDA Margin
26.72%
25.27%
20.11%
25.17%
22.94%
22.52%
23.88%
21.69%
13.29%
-22.56%
19.91%
Other Income
126.50
144.40
206.20
157.10
79.20
53.10
55.90
56.70
309.40
1,035.50
37.02
Interest
64.00
70.90
61.50
26.00
29.30
8.90
1.70
8.10
12.40
24.30
16.89
Depreciation
519.60
447.80
385.10
277.20
248.70
221.00
203.60
179.30
175.80
156.70
140.14
PBT
1,297.90
1,019.40
588.70
833.40
569.00
519.00
537.70
408.30
398.40
447.10
351.47
Tax
311.00
212.30
156.90
161.60
142.20
95.70
106.90
97.50
55.90
72.10
48.67
Tax Rate
23.96%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
13.85%
PAT
986.90
904.40
351.10
595.80
528.70
497.40
413.80
508.90
341.60
367.50
293.25
PAT before Minority Interest
870.20
1,001.70
431.80
671.80
587.40
528.40
430.80
512.70
342.50
375.00
302.81
Minority Interest
-116.70
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
-9.56
PAT Margin
15.63%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
16.37%
20.35%
12.38%
PAT Growth
10.31%
157.59%
-41.07%
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
25.32%
 
Unadjusted EPS
6.99
15.30
6.31
10.39
28.04
24.87
21.09
25.99
17.27
18.79
15.08

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
1,757.85
Share Capital
300.00
300.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
5,720.80
4,812.30
4,670.20
3,933.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
1,595.96
Non-Current Liabilities
2,123.20
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
564.44
Secured Loans
1,539.50
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
331.50
Unsecured Loans
2.10
2.80
3.90
11.40
11.40
25.80
40.00
60.50
65.80
182.11
Long Term Provisions
66.10
49.30
36.00
29.90
15.00
7.80
4.00
0.00
1.00
0.00
Current Liabilities
3,037.60
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
581.73
Trade Payables
1,198.30
1,005.30
739.70
609.80
429.30
347.20
345.50
347.80
296.50
230.86
Other Current Liabilities
1,373.80
870.10
698.20
527.10
706.20
612.30
313.10
269.20
375.90
260.05
Short Term Borrowings
261.20
130.30
97.20
394.90
261.00
243.50
84.80
187.30
247.40
0.00
Short Term Provisions
204.30
135.60
143.20
133.90
158.20
176.60
246.50
211.50
140.80
90.83
Total Liabilities
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
Net Block
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
1,337.93
Gross Block
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
1,837.13
Accumulated Depreciation
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
499.20
Non Current Assets
7,044.90
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
1,460.60
Capital Work in Progress
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
75.52
Non Current Investment
182.50
63.80
188.80
26.80
0.00
64.50
64.50
64.20
60.90
47.16
Long Term Loans & Adv.
401.50
437.20
319.70
350.10
336.90
252.00
241.60
181.00
140.20
0.00
Other Non Current Assets
91.00
144.40
176.20
51.00
169.60
64.50
47.20
32.30
0.00
0.00
Current Assets
4,822.80
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
1,477.21
Current Investments
829.30
611.40
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
383.42
Inventories
1,031.60
722.50
635.30
542.40
452.70
376.60
398.40
378.30
413.70
371.64
Sundry Debtors
1,291.80
1,063.90
883.20
714.50
770.50
599.80
509.70
491.70
495.80
446.13
Cash & Bank
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
139.93
Other Current Assets
612.90
373.30
395.80
73.60
171.60
157.60
136.90
114.30
56.70
136.10
Short Term Loans & Adv.
46.40
54.70
24.10
227.10
75.80
81.80
81.40
37.10
20.20
120.28
Net Current Assets
1,785.20
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
895.48
Total Assets
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,154.60
662.10
640.00
526.40
210.70
560.70
471.20
564.10
798.50
443.81
PBT
1,214.90
610.00
849.70
1,227.40
624.10
537.70
610.20
395.20
447.10
351.47
Adjustment
260.30
355.70
204.40
-409.40
74.00
134.00
147.30
144.80
163.50
159.65
Changes in Working Capital
-29.10
-106.50
-211.10
-44.80
-354.00
37.70
-192.30
98.00
269.20
-34.53
Cash after chg. in Working capital
1,446.10
859.20
843.00
773.20
344.10
709.40
565.20
638.00
879.80
476.60
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-291.50
-197.10
-203.00
-246.80
-133.40
-148.70
-94.00
-73.90
-81.30
-32.79
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-713.80
-684.00
-498.50
-954.00
-508.70
-938.10
-375.80
-359.50
-314.50
-226.07
Net Fixed Assets
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
-55.73
Net Investments
184.70
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
-71.95
Others
-617.90
-195.40
-203.30
2,951.00
-779.30
-741.10
-200.00
-113.20
-112.27
-98.39
Cash from Financing Activity
-241.70
-239.70
-177.50
1,086.70
186.20
426.00
-8.60
-186.30
-274.60
-85.21
Net Cash Inflow / Outflow
199.10
-261.60
-36.00
659.10
-111.80
48.60
86.80
18.30
209.40
132.53
Opening Cash & Equivalents
449.00
710.20
757.50
462.60
557.00
474.00
369.00
359.00
139.90
11.81
Closing Cash & Equivalent
659.30
449.00
710.20
1,127.00
462.60
557.00
474.00
369.00
359.00
143.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
50.17
42.59
39.74
33.61
26.93
24.21
21.59
18.16
16.25
14.13
ROA
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
11.05%
ROE
18.00%
8.74%
15.26%
16.17%
17.22%
15.68%
21.50%
16.59%
20.58%
19.14%
ROCE
16.10%
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
17.12%
Fixed Asset Turnover
0.85
0.73
0.89
1.05
1.09
1.12
1.11
1.06
0.97
1.42
Receivable days
77.96
86.05
74.35
80.16
80.09
69.48
72.22
84.37
93.20
60.98
Inventory Days
58.05
60.00
54.81
53.71
48.47
48.54
56.01
67.67
77.71
51.83
Payable days
86.75
87.98
78.68
68.27
58.15
55.73
65.24
70.25
70.62
41.52
Cash Conversion Cycle
49.26
58.07
50.48
65.60
70.42
62.29
62.99
81.79
100.29
71.30
Total Debt/Equity
0.40
0.44
0.48
0.61
0.35
0.30
0.10
0.12
0.17
0.30
Interest Cover
18.12
10.57
33.05
25.90
71.12
317.29
76.33
33.13
19.40
21.81

News Update


  • USFDA completes PAI, GMP inspection at Biocon’s Bengaluru facility
    27th Jan 2020, 10:03 AM

    The agency issued a Form 483, with five observations

    Read More
  • Biocon reports 7% fall in Q3 consolidated net profit
    24th Jan 2020, 10:19 AM

    Total consolidated income of the company increased by 13.89% at Rs 1783.90 crore for Q3FY20

    Read More
  • Biocon’s arm receives Rs 536 crore subscription money from Activ Pine LLP
    22nd Jan 2020, 10:37 AM

    Consequently, the Board of BBIL has approved the allotment of 50,25,463 equity shares of Rs 10 each at a price of Rs 1,067.07 per equity share to Activ Pine LLP

    Read More
  • USFDA completes inspection at Biocon’s arm’s Oral Solid Dosage manufacturing facility
    20th Jan 2020, 09:26 AM

    The inspection of the Bengaluru facility took place between January 13 and January 17, 2020

    Read More
  • Biocon, BBIL, Activ Pine LLP enter into share subscription agreement
    10th Jan 2020, 11:30 AM

    True North Fund VI LLP shall subscribe to 50.25 lakh equity shares of BBIL, at a price of Rs 1,067.07 per equity share

    Read More
  • True North to invest Rs 536.25 crore in Biocon's arm
    6th Jan 2020, 15:20 PM

    Post the completion of this transaction, Biocon will hold 96.07% stake in Biocon Biologics

    Read More
  • Biocon incorporates wholly owned subsidiary company
    26th Dec 2019, 16:40 PM

    The business of subsidiary company is in line with the main business activities of the company

    Read More
  • Biocon, Equillium expand exclusive licensing agreement for Itolizumab
    13th Dec 2019, 08:55 AM

    The license agreement is for developing and commercializing itolizumab in Australia and New Zealand

    Read More
  • Biocon’s arm to unlock universal access to Insulins Globally
    4th Dec 2019, 10:23 AM

    The company to unlock affordable access to quality insulins for people with diabetes across the world

    Read More
  • Biocon, Mylan NV launch Ogivri in US
    3rd Dec 2019, 09:04 AM

    Ogivri is available in a 420 mg multi-dose vial and a 150 mg single-dose vial

    Read More
  • USFDA approves Biocon’s sBLA for Pegfilgrastim new manufacturing facility
    27th Nov 2019, 09:18 AM

    This additional approval of its new manufacturing facility for Pegfilgrastim in Bengaluru will enable Biocon Biologics to scale up capacity multi-fold

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.